Oncolytics Biotech Wins FDA Fast Track for Pelareorep
SAN DIEGO, July 20, 2026 Oncolytics Biotech announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SAN DIEGO, July 20, 2026 Oncolytics Biotech announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
San Diego, California, USA, April 6, 2026 FDA Engagement Signals Registrational Pathway Progress In a key development for oncolytic...
